Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy

被引:361
作者
Bullock, AN
Henckel, J
Fersht, AR
机构
[1] Univ Cambridge, Chem Lab, Cambridge CB2 2QH, England
[2] MRC Ctr, Cambridge Ctr Prot Engn, Cambridge CB2 2QH, England
关键词
tumour suppressor; stability; denaturation; activity; protein;
D O I
10.1038/sj.onc.1203434
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
The tumour suppressor p53 is mutated in half of all human cancers, most frequently with missense substitutions in its core domain. We present a new assessment of the mutation database based on quantitative folding and DNA-binding studies of the isolated core domain. Our data identify five distinct mutant classes that correlate with four well-defined regions of the core domain structure. On extrapolation to 37 degrees C the wild-type protein has a stability of 3.0 kcal/mol, This also emerges as an oncogenic threshold: all beta-sandwich mutants destabilized by this amount (50% denatured) are expected to promote cancer. Other weakly destabilizing mutations are restricted to loop 3 in the DNA-binding region, Drugs that stabilize mutant p53 folding have the potential to reactivate apoptotic signalling pathways in tumour cells either by transactivation-dependent or independent pathways. Using an affinity ligand as a proof of principle we have recovered the thermodynamic stability of the hotspot G245S. With reference states for the five mutant classes as a guide, future therapeutic strategies may similarly stabilize partially structured or binding states of mutant p53 that restore limited p53 pathways to tumour suppression.
引用
收藏
页码:1245 / 1256
页数:12
相关论文
共 71 条
[1]
A PROTEOLYTIC FRAGMENT FROM THE CENTRAL REGION OF P53 HAS MARKED SEQUENCE-SPECIFIC DNA-BINDING ACTIVITY WHEN GENERATED FROM WILD-TYPE BUT NOT FROM ONCOGENIC MUTANT P53-PROTEIN [J].
BARGONETTI, J ;
MANFREDI, JJ ;
CHEN, XB ;
MARSHAK, DR ;
PRIVES, C .
GENES & DEVELOPMENT, 1993, 7 (12B) :2565-2574
[2]
Mechanisms of p53-mediated apoptosis [J].
Bates, S ;
Vousden, KH .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 55 (01) :28-37
[3]
Bennett WP, 1999, J PATHOL, V187, P8, DOI 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO
[4]
2-Y
[5]
Correcting temperature-sensitive protein folding defects [J].
Brown, CR ;
HongBrown, LQ ;
Welch, WJ .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 99 (06) :1432-1444
[6]
Thermodynamic stability of wild-type and mutant p53 core domain [J].
Bullock, AN ;
Henckel, J ;
DeDecker, BS ;
Johnson, CM ;
Nikolova, PV ;
Proctor, MR ;
Lane, DP ;
Fersht, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (26) :14338-14342
[7]
The structure of a PKD domain from polycystin-1: Implications for polycystic kidney disease [J].
Bycroft, M ;
Bateman, A ;
Clarke, J ;
Hamill, SJ ;
Sandford, R ;
Thomas, RL ;
Chothia, C .
EMBO JOURNAL, 1999, 18 (02) :297-305
[8]
P53-DEPENDENT APOPTOSIS IN THE ABSENCE OF TRANSCRIPTIONAL ACTIVATION OF P53-TARGET GENES [J].
CAELLES, C ;
HELMBERG, A ;
KARIN, M .
NATURE, 1994, 370 (6486) :220-223
[9]
14-3-3σ is required to prevent mitotic catastrophe after DNA damage [J].
Chan, TA ;
Hermeking, H ;
Lengauer, C ;
Kinzler, KW ;
Vogelstein, B .
NATURE, 1999, 401 (6753) :616-620
[10]
In vitro analysis of the dominant negative effect of p53 mutants [J].
Chène, P .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 281 (02) :205-209